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Hormone and receptor activator
of NF‑κB (RANK) pathway gene expression
in plasma and mammographic breast density
in postmenopausal women
Rachel Mintz1, Mei Wang2, Shuai Xu2, Graham A. Colditz2,3, Chris Markovic4 and Adetunji T. Toriola2,3*

Abstract
Background: Hormones impact breast tissue proliferation. Studies investigating the associations of circulating
hormone levels with mammographic breast density have reported conflicting results. Due to the limited number of
studies, we investigated the associations of hormone gene expression as well as their downstream mediators within
the plasma with mammographic breast density in postmenopausal women.
Methods: We recruited postmenopausal women at their annual screening mammogram at Washington University
School of Medicine, St. Louis. We used the NanoString nCounter platform to quantify gene expression of hormones
(prolactin, progesterone receptor (PGR), estrogen receptor 1 (ESR1), signal transducer and activator of transcription
(STAT1 and STAT5), and receptor activator of nuclear factor-kB (RANK) pathway markers (RANK, RANKL, osteoprotegerin, TNFRSF18, and TNFRSF13B) in plasma. We used Volpara to measure volumetric percent density, dense volume,
and non-dense volume. Linear regression models, adjusted for confounders, were used to evaluate associations
between gene expression (linear fold change) and mammographic breast density.
Results: One unit increase in ESR1, RANK, and TNFRSF18 gene expression was associated with 8% (95% CI 0–15%,
p value = 0.05), 10% (95% CI 0–20%, p value = 0.04) and % (95% CI 0–9%, p value = 0.04) higher volumetric percent
density, respectively. There were no associations between gene expression of other markers and volumetric percent
density. One unit increase in osteoprotegerin and PGR gene expression was associated with 12% (95% CI 4–19%, p
value = 0.003) and 7% (95% CI 0–13%, p value = 0.04) lower non-dense volume, respectively.
Conclusion: These findings provide new insight on the associations of plasma hormonal and RANK pathway gene
expression with mammographic breast density in postmenopausal women and require confirmation in other studies.
Keywords: Mammographic breast density, Hormones, RANK, RANKL, Gene expression
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Background
Mammographic breast density (MBD), a strong risk factor for breast cancer, reflects the amount of epithelial and
stromal tissues relative to adipose tissue in the breast
[1]. Fat appears darker than epithelium and stroma on
a mammogram. Women with greater than 75% density on a mammogram have a 4–6 times greater risk of
developing breast cancer compared to women with less
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than 5% density [2]. The Interventional Breast Cancer
Intervention Study demonstrated that a pharmacologically induced 10% decrease in MBD over time is clinically
meaningful in the context of breast cancer risk reduction
[3].
MBD declines post menopause as endogenous hormone levels decline, indicating an association with hormones and age [4]. MBD also increases with menopausal
hormone therapy use [5–8], and stopping hormone therapy conversely reverts MBD to prior levels [9]. Nevertheless, studies investigating the associations of circulating
hormone levels with MBD report conflicting results [10–
17]. Few studies have addressed the genomic signatures
of MBD or investigated how hormone gene expression
(e.g., progesterone and prolactin) in tissue or blood may
be associated with MBD [18–20]. Gene expression may
capture transcriptional changes associated with MBD
and could help identify biomarkers of MBD. Breast tissue
estrogen receptor 1 (ESR1) gene expression was shown
to be negatively associated with percent density in postmenopausal women [21].
We have reported that the receptor activator of nuclear
factor kappa-Β ligand (RANKL) gene expression is positively associated with MBD in premenopausal women
[22], but there are no data on the associations of plasma
RANKL and other tumor necrosis factor receptor superfamily members (e.g., TNFRSF18 and TNFRSF13B) gene
expression with MBD in postmenopausal women. Preclinical studies have shown that RANK/RANKL signaling
is the major mediator of progesterone-induced mammary epithelial proliferation and expansion of mammary stem cells [23]. Progesterone and prolactin also
upregulate RANKL expression [24, 25] and interact with
the RANK/RANKL pathway through signal transducer
and activator of transcription (STAT) signaling [26, 27].
Despite the extensive crosstalk between the hormones
and the RANK pathway identified in preclinical studies,
their correlations have not yet been evaluated in population-based studies.
Our objectives in this study are twofold: investigate for
the first time the (1) associations of plasma hormone and
RANK pathway gene expression with volumetric measures of MBD in postmenopausal women; (2) correlations
between hormone and RANK pathway gene expression.
Study findings should provide new insight into gene
expression profiles that may influence MBD in postmenopausal women.

Methods
Study population

We recruited 400 postmenopausal women during annual
routine screening mammography at the Joanne Knight
Breast Health Center (BHC) at the Siteman Cancer
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Center at Washington University School of Medicine, St.
Louis, MO between October 2017 and September 2018.
Complete data on gene expression and MBD were available and analyzed for 368 women.
Women were eligible to participate in the study if they
were: (1) aged 50–64 years; (2) postmenopausal; (3) able
to comply with all required study procedures and schedule, including the provision of blood samples at the time
of enrollment. Exclusion criteria included: (1) cancer history; (2) history of breast augmentation, reduction, or
implants; (3) history of denosumab (a monoclonal antibody that binds RANKL) use in the previous 6 months;
(4) history of selective estrogen receptor modulators use
in the previous 6 months. We used a modification of the
National Comprehensive Cancer Network definition [28],
which does not require the measurement of plasma hormone levels to define postmenopausal status. A woman
was considered postmenopausal if she had a prior bilateral oophorectomy, was age 60 or older, or if under age
60, had been amenorrheic for at least 12 months.
On the day of the screening mammogram, study participants completed a blood draw and responded to a
questionnaire on breast cancer risk factors. Blood samples were processed and stored at − 80 °C within 60 min
of collection. A study coordinator measured study participants’ heights using a stadiometer and weights using
the OMRON Full Body Sensor Body Composition Monitor and Scale model HBF-514FC. Body mass index (BMI)
was derived by dividing current weight (kg) by height (m)
squared (kg/m2). Approval for the study was granted by
the Institutional Review Board at Washington University School of Medicine, St. Louis, MO. All participants
provided written informed consent to participate in the
study.
Mammographic breast density assessment

We used Volpara [version 1.5, (Matakina Technology
Limited, Wellington, New Zealand)] to obtain automated,
objective MBD measurements. Volpara density measurements are highly reproducible [29–31]. Volpara uses a
relative physics approach and a computerized algorithm
that compares. X-ray attenuation at each pixel to a reference pixel within the breast that is assumed to comprise
all adipose/non-dense tissue. Using known X-ray attenuation coefficients for fibroglandular/dense and non-dense
tissue, Volpara can then estimate the relative thickness
of dense and non-dense tissue at each pixel in the image.
As the pixel dimensions are known, these thickness estimates can then be converted to volumes and summed
across the breast to determine the absolute volumes of
dense volume (DV, c m3), and non-dense volume (NDV,
cm3) in cubic centimeters. i.e., tissue volume at each
pixel = tissue thickness × pixel width × pixel length. The
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total breast volume is determined using Volpara’s proprietary segmentation of the breast and model of the breast
edge under compression, and the reported compressed
breast thickness. The volumetric breast density (%), can
then be determined by taking the ratio of the absolute
dense volume to the total breast volume, expressed as
a percentage. i.e., Volumetric breast density (VPD, %),
% = (volume fibroglandular tissue/volume breast) × 100.
In comparison with Breast Imaging Reporting and Data
System (BI-RADS) fifth edition, Volpara VPD ranges
from 0.5 to 34.5%, which translate to: < 3.5% (a, almost
entirely fatty breasts); ≥ 3.5–< 7.5% (b, scattered areas
of fibroglandular density); ≥ 7.5–< 15.5% (c, heterogeneously dense breasts); ≥ 15.5 (d, extremely dense breasts).
Plasma gene expression

We performed RNA profiling to quantify gene expression in the plasma, not in the breast tissue to gain further knowledge into how these biomarkers are associated
with MBD outside that gleamed from circulating protein
levels alone. While mRNA expression and protein levels are correlated across cell lines [32, 33], many factors,
including post-translational stability influence circulating
protein levels, hence, the correlations of mRNA and their
circulating protein levels may be weak [34].
We designed a custom NanoString nCounter codeset
for quantitative RNA profiling of the following genes: (1)
hormones: prolactin (PRL), progesterone receptor (PGR),
estrogen receptor 1 (ESR1), signal transducer and activator of transcription 1 (STAT1), and signal transducer and
activator of transcription 5 (STAT5); (2) RANK pathway:
RANK, RANKL, tumor necrosis factor receptor superfamily member 13B (TNFRSF13B), tumor necrosis factor
receptor superfamily member 18 (TNFRSF18) and osteoprotegerin (OPG). We selected these genes based on data
from preclinical studies suggesting crosstalk between
the RANK pathway markers (RANK, RANKL, OPG)
[35, 36] and specific hormone signaling (PRL, ESR1,
PGR, STAT1, and STAT5) [27, 37–39]. TNFRSF13 and
TNFRSF18 are also RANK pathway markers that could
have biological relevance, but there is limited or no data
on their associations with MBD. Thus, we designed targets for those genes as well with NanoString.
RNA profiling for gene expression was performed at
the McDonnell Genome Institute, Washington University School of Medicine in St. Louis. Gene expression
levels were measured in plasma RNA isolated, using the
NanoString “nCounter XT Codeset Gene Expression
Assays” protocol (NanoString Technologies, Seattle, WA,
USA). Quality control was performed as recommended
by the manufacturer. This NanoString protocol has been
validated extensively in tissue [40–43] and blood [44, 45].
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Plasma samples were processed according to the manufacturer’s recommendations. Following hybridization,
samples were processed on the NanoString Prep Station
where they were purified and immobilized on a sample
cartridge for data collection. The output for each sample
was imported into nSolver Analysis Software for Quality
Control and analysis. Binding densities ranged from 0.09
to 0.34. Digital transcript counts from the NanoString
nCounter assay were normalized using the housekeeping
genes following the manufacturer’s guidelines.
Statistical analyses

Statistical analyses were performed with the NanoString
nSolver Analysis System 4.0 (NanoString Technologies) using the Advanced Analysis package 2.0 and its
custom analysis pipeline. VPD, DV, and NDV were all
log-transformed to ensure the normality of the residuals. All analyses were performed on curated log2 transformed normalized counts. We evaluated correlations
between the genes as well as between the genes and age
and BMI using Pearson correlation (r). In addition, we
evaluated correlations of the genes adjusted for age and
BMI. We also performed correlation analysis in a subset
of our study participants (82 women with dense breasts)
who had both circulating RANK, RANKL, and OPG and
mRNA gene expression data. Genes were tested for differential expression to MBD and adjusted for the following confounding variables: race (Non-Hispanic white/
African-American/Others), current age (continuous,
years), BMI (continuous, kg/m2), age at menarche (continuous), menopausal hormone therapy use (ever/never),
parity, and age at first birth (continuous). For each gene
expression, a single linear regression was fit using all
selected variables to predict expression. The fold change
is then estimated using a simplified negative binomial
model, presented here as ‘linear fold change.’ The 95%
confidence interval for the linear fold change is also presented, along with a p value. A value of p < 0.05 was considered statistically significant. These linear fold changes
are herein discussed in terms of percentage increases or
decreases such that a linear fold change of 1.04 corresponds to a 4% increase in MBD, and a 0.96 linear fold
change corresponds to a 4% decrease in MBD. We further used multinomial logistic regression models to evaluate the associations of growth factor gene expression
with categories of VPD, adjusted for confounders.

Results
The mean age of the study participants was 57.9 years
(Table 1). The mean BMI was 31.3 kg/m2, which is consistent with the BMI of women attending screening
mammograms at the Joanne Knight Breast Health Center.
Many participants were Non-Hispanic White (62%) and
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Table 1 Characteristics of 368 postmenopausal women recruited during annual screening mammogram at the Joanne Knight Breast
Health Center, Washington University School of Medicine, St. Louis, MO
Characteristic

Number

Mean ± SD/percentagesa

Age (years)

368

Age at menarche (years)

361

57.9 ± 3.8

Body mass index (kg/m2)

367

31.3 ± 7.7

Non-Hispanic White

228

62.0

Black or African-American

131

Race/ethnicity

Other

12.8 ± 1.7

35.6

9

2.4

Education
High school or less than high school

64

17.4

Post high school training or some college

106

28.8

College graduate

106

28.8

Postgraduate
Missing

90

24.5

2

0.5

Alcohol use
No

149

Yes

217

Missing

2

40.5
59.0
0.5

Family breast cancer history
No

271

Yes

91

24.7

6

1.6

Missing

73.6

Parity and age at first birth
Nulliparous

63

17.1

1–2 children, < 25 years

86

23.4

1–2 children, 25–29 years

64

17.4

1–2 children, ≥ 30 years

55

15.0

66

17.9

≥ 3 children, ≥ 25 years

33

9.0

1

0.3

≥ 3 children, < 25 years
Missing

Breast feeding
No

139

37.8

Yes

164

44.6

Not applicable
Missing

64

17.4

1

0.3

Menopausal hormone therapy use
No

245

66.6

Yes

122

33.2

Missing

1

0.3

Mammographic breast density
Volumetric percent density (%)
  VPD < 3.5%
  VPD ≥ 3.5% and < 7.5%

  VPD ≥ 7.5% and < 15.5%

  VPD ≥ 15.5%

a

368
52

6.2 ± 4.1

234
68
14

Dense Volume (cm3)

368

Non-dense Volume (cm3)

368

Mean ± Standard deviation (SD) presented for continuous variables. Percentages presented for categorical variable

121.2 ± 125.1

2134.4 ± 2062.6
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African-American (35.6%). The mean VPD was 6.2% (BIRADS category b). The mean DV and NDV were 121.2
cm3 and 2134.4 cm3, respectively.
There were positive correlations between progesterone and OPG plasma gene expression (r = 0.65,
p value < 0.0001), STAT1 and STAT5 (r = 0.59, p
value < 0.0001) plasma gene expression (Table 2), ESR1
and progesterone plasma gene expression (r = 0.43, p
value < 0.0001) as well as prolactin and STAT5 (r = 0.43,
p value < 0.0001) plasma gene expression. TNFRSF18
plasma gene expression was positively correlated with the
nine other markers. RANK plasma gene expression was
negatively correlated with prolactin, STAT1, and STAT5
plasma gene expression. BMI was weakly inversely correlated with gene expression of RANK pathway markers
(Table 2) but not with hormone gene expression, and further adjusting the correlations for age and BMI had negligible impact on the correlation coefficients (Additional
file 1: Table S1).
Table 3 shows the associations between hormone and
RANK pathway plasma gene expression and VPD. Of
the 10 markers evaluated ESR1, RANK, and TNFRSF18
plasma gene expression were associated with VPD.
A one-unit increase in ESR1, RANK, and TNFRSF18
plasma gene expression was associated with 8% (95%
CI 0–15%, p value = 0.05), 10% (95% CI 0–20%, p
value = 0.04), and 4% (95% CI 0–9%, p value = 0.04)
higher VPD, respectively.
We also investigated the associations of plasma gene
expression across categories of VPD using multinominal logistic regression models (Table 4). The associations
were similar to what we observed evaluating gene expression in the continuous form. We, however, also observed
positive associations for RANKL and OPG plasma
gene expression when we compared extremes of MBD.
Women with extremely dense breasts (VPD > 15.5%; BIRADS d) had a 73% (95% CI 1.05–2.85, p value = 0.03)
higher plasma RANKL gene expression, and 86% (95%
CI 1.10–3.14, p value = 0.02) higher plasma OPG gene
expression compared with women with almost entirely
fatty breasts (VPD < 3.5%; BI-RADS a). RANKL and OPG
plasma gene expression was not higher among women
with heterogeneously dense breasts (VPD ≥ 7.5% and
< 15.5%; BI-RADS c) compared with women with almost
entirely fatty breasts.
In a subset of our study participants (82 women with
dense breasts) who had both circulating RANK, RANKL,
and OPG and mRNA gene expression data (Additional
file 1: Table S2), we observed mild positive correlations
between circulating protein levels and the mRNA gene
expression for RANK (r = 0.26, p value = 0.03), RANKL
(r = 0.23, p value = 0.04) but not for OPG (r = − 0.03, p
value = 0.81).
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We further evaluated the associations of plasma
gene expression with NDV and DV (Additional file 1:
Table S3). A one-unit increase in plasma OPG, PGR, and
TNFRSF13B gene expression was associated with 12%
(95% CI 4–19%, p value = 0.003), 7% (95% CI 0–13%, p
value = 0.04), and 5% lower (95% CI 1–9%, p value = 0.02)
NDV, respectively. Only plasma OPG gene expression
was associated with DV: a one-unit increase in OPG was
associated with 8% (95% CI 0–15%, p value = 0.05) lower
DV.

Discussion
To the best of our knowledge, this is the first study to
investigate the associations of plasma hormone and
RANK pathway gene expression with volumetric measures of MBD in postmenopausal women. We observed
positive associations of ESR1, RANK, and TNFRSF18
plasma gene expression with VPD and inverse associations of PGR and OPG plasma gene expression with
NDV.
VPD represents the stromal and epithelial components
of fibroglandular breast tissue and is positively associated
with breast cancer risk [46–48] while NDV represents
the adipose component of breast tissue and is inversely
associated with breast cancer risk in many studies [46, 49,
50]. Our finding of a positive association of plasma ESR1
gene expression with VPD is similar to that reported for
circulating estradiol and percent density in some studies
[11, 51, 52], while other studies have reported inverse [12,
16, 17], or no associations between circulating estradiol
and percent density [13, 15, 53]. These results are difficult to directly compare as they examine plasma gene
expression or circulating hormone levels. Taken together,
they suggest that a singular circulating estradiol level,
as determined in these studies, may not be sufficient to
serve as a reliable proxy for estrogen activity.
ESR1 (ERα) regulates estrogen activity, and the ESR1
gene encodes a transcription factor with an estrogen binding domain, activating domain, and estrogen
response element [54, 55]. Once estrogen binds to ESR1,
proliferation is induced in both normal and neoplastic
breast epithelial cells through ESR1 signaling of estrogenresponsive genes [56]. Thus, if ESR1 gene expression is
increased this may lead to greater proliferation of breast
tissue, culminating in greater MBD and increased breast
cancer risk. This mechanism could explain the association between plasma ESR1 gene expression and VPD
identified in our study.
Interestingly, a previous study using data from 79
women reported a positive association of serum estradiol
level but reported an inverse association of breast tissue
ESR1 gene expression with percent density in postmenopausal women [21]. The authors of this study pointed out

5.38 (4.42–7.42)

4.4 (3.08–7.00)

14.62 (10.79–16.86)

11.93 (8.09–12.99)

6.33 (5.72–6.93)

2.93 (2.16–3.70)

4.12 (3.57–4.67)

6.70 (6.09–7.31)

7.42 (7.04–7.80)

ESR1

PGR

STAT1

STAT5

RANK

RANKL

OPG

TNFRSF13B

TNFRSF18

p < 0.01
1.00

− 0.16

0.07

p = 0.92

0.01

p = 0.02

− 0.12

p = 0.40

0.04

p = 0.19

*

Statistically significant correlations (p < 0.05) are in bold

BMI Body Mass Index (kg/m2)

0.17

0.17

p < 0.01

p = 0.01

− 0.13

p = 0.02

− 0.12

p = 0.04

1.00

0.15

− 0.08

p = 0.11

− 0.15

p < 0.01

− 0.10

1.00

− 0.06

p = 0.24

− 0.21

p < 0.01

0.65
p < 0.01

p < 0.01

1.00

− 0.02

p = 0.65

− 0.17

p < 0.01

p = 0.05

p < 0.01

0.41

p < 0.01

0.28

OPG

p < 0.01

− 0.18

0.59
p < 0.01

0.25
p < 0.01

0.10

p < 0.01

− 0.02

1.00

− 0.05

p = 0.36

− 0.15

p < 0.01

p = 0.10

p = 0.64

0.06

1.00

p < 0.01

0.27

p = 0.22

0.03

− 0.07

− 0.04

p = 0.08

p = 0.04

− 0.09

p = 0.50

0.04

0.08

p < 0.01

p = 0.18

0.08

p = 0.70

0.02

RANKL

p = 0.43

− 0.16

p < 0.01

RANK

p = 0.42

− 0.11

0.43

p < 0.01

0.39

STAT5

p = 0.20

0.07

1.00

0.25
p < 0.01

0.25
p < 0.01

STAT1

PGR

p = 0.17

0.01

p = 0.79

0.01

ESR1

p = 0.99

1.00

PRL

p = 0.28

− 0.05

BMI

p = 0.34

0.05

Age

Pearson’s correlation coefficients were calculated. Gene expression levels were log2 transformed

5.81 (4.60–6.83)

Mean (Range)

PRL

Gene

Table 2 Correlations between hormones and RANK pathway gene expression in postmenopausal women

1.00

p = 0.14

0.07

p = 0.90

− 0.01

p < 0.01

0.19

− 0.06

p = 0.25

p < 0.01

− 0.22

1.00

p < 0.01

0.23

p < 0.01

0.25

p < 0.01

0.14

p < 0.01

0.32

p < 0.01

0.35

p < 0.01

0.20

0.30
p < 0.01

0.10

p < 0.01

0.22

p < 0.01

0.24

TNFRSF18

p = 0.04

p < 0.01

0.20

− 0.18

p < 0.01

TNFRSF13B
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Table 3 Associations of hormone, RANK pathway gene
expression with volumetric percent density
mRNA gene
expression

Linear fold
change

Lower
confidence
limit

Upper
confidence
limit

p value

PRL

1.00

0.95

1.06

0.97

ESR1

1.08

1.00

1.15

0.05

PGR

1.07

0.94

1.22

0.29

STAT1

1.00

0.94

1.07

0.96

STAT5

0.98

0.95

1.02

0.29

RANK

1.10

1.00

1.20

0.04

RANKL

1.10

0.94

1.29

0.26

OPG

1.10

0.94

1.28

0.23

TNFRSF13B

1.02

0.95

1.11

0.56

TNFRSF18

1.04

1.00

1.09

0.04

Multivariable model adjusted for race (Non-Hispanic White, Black or AfricanAmerican, Other), current age (continuous), BMI (continuous), age at first
menarche (continuous), menopausal hormone therapy use (Yes, No, Missing),
combined parity, and age at first birth (categorical)

that increased levels of estradiol have also been shown
to decrease levels of ESR1 in breast cancer [57] and thus
reasoned that the association between reduced ESR1 and
high MBD may reflect high levels of plasma estradiol.

Therefore, longitudinal studies that concomitantly
explore the associations between circulating estradiol
and plasma ESR1 gene expression with MBD are warranted in postmenopausal women.
The associations of serum RANK and RANKL gene
expression we observed are similar to our results in
premenopausal women [22]. RANK causes mammary
epithelial cell proliferation perhaps via upregulation of
cyclin D1 [58], and RANKL is essential for the development, formation, and differentiation of mammary glands
[25, 59]. Some studies have reported associations of the
RANK pathway with breast cancer pathogenesis, while
others have not [60–63]. The positive association of
plasma RANKL gene expression with MBD was limited
to when we compared women at the extremes of MBD
profiles, which suggests a nonlinear association between
RANKL gene expression and MBD.
In addition, women with extremely dense breasts
had higher OPG gene expression than women with
almost entirely fatty breasts. OPG gene expression was
inversely associated with DV and NDV. The findings
were unexpected given that OPG competes with RANK
for RANKL binding, thereby blocking RANK activation
[64]. Hence, we hypothesized that OPG mRNA expression would be negatively associated with VPD and DV.

Table 4 Associations of hormone, RANK pathway gene expression with categories of volumetric percent density
VPD < 3.5% N = 52

VPD ≥ 3.5 and < 7.5%
N = 234

VPD ≥ 7.5 and < 15.5%
N = 68

VPD ≥ 15.5% N = 14

Ref

1.03 (0.93–1.13)

1.08 (0.93–1.24)

0.93 (0.76–1.14)

p = 0.57

0.99 (0.88–1.12)

p = 0.31

1.00 (0.85–1.18)

p = 0.48

p = 0.88

1.01 (0.81–1.27)

p = 1.00

1.12 (0.84–1.51)

p = 0.06

p = 0.92

1.06 (0.94–1.19)

p = 0.44

1.09 (0.94–1.27)

p = 0.14

p = 0.36

1.03 (0.96–1.1)

p = 0.27

1.01 (0.93–1.10)

p = 1.00

p = 0.38

1.22 (1.05–1.43)

p = 0.77

1.23 (1.01–1.51)

p = 0.78

p = 0.01

0.87 (0.65–1.17)

p = 0.04

0.99 (0.68–1.45)

p = 0.02

p = 0.37

1.13 (0.86–1.48)

p = 0.97

1.11 (0.78–1.57)

p = 0.03

p = 0.37

0.98 (0.85–1.12)

p = 0.57

0.89 (0.74–1.07)

p = 0.02

p = 0.75

1.13 (1.06–1.22)

p = 0.21

1.11(1.02–1.22)

p = 0.06

p = 0.001

p = 0.02

p = 0.002

Linear fold change (confidence interval), p value
PRL
ESR1
PGR
STAT1
STAT5
RANK
RANKL
OPG
TNFRSF13B
TNFRSF18
VPD volumetric percent density

Ref
Ref
Ref
Ref
Ref
Ref
Ref
Ref
Ref

1.28 (0.99–1.64)

1.41 (0.90–2.23)

1.00 (0.79–1.27)

0.98 (0.86–1.12)

1.45 (1.06–1.99)

1.73 (1.05–2.85)

1.86 (1.10–3.14)

1.31 (0.99–1.74)

1.26 (1.09–1.45)
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Our findings are similar to a study that reported low
OPG serum levels to be associated with high mammographic breast density (VPD and DV) [65] and contrary
to another study that found no association between OPG
and VPD [63]. Furthermore, some findings from preclinical studies show that OPG expression in tissue may be
associated with breast tumor formation [36, 66]. Thus,
the association of OPG with mammographic breast density remains unclear and deserves to be studied further.
Due to the limited data on the role of OPG in breast proliferation, development, and function in humans, clinical
studies are needed to elucidate the role of OPG in MBD
and breast cancer development as well as how these associations may be mediated by estrogen and progesterone,
given the correlations we observed across these genes.
Plasma progesterone receptor gene expression was not
associated with VPD but was associated with NDV. Some
studies have reported associations between circulating
progesterone and percent breast density and percent
dense area [13, 67, 68], while others have not [12, 15, 17].
Our finding is similar to another study that found a positive association of progesterone with absolute non-dense
breast volume in premenopausal women [69]. NDV is
inversely associated with breast cancer risk [46, 49, 50],
suggesting that elevated progesterone gene expression
may be associated with elevated breast cancer risk in
postmenopausal women.
We found no association between plasma prolactin
gene expression and VPD, consistent with findings from
previous studies on circulating prolactin and percent
dense area in postmenopausal women [17, 70], but not
with others that have reported positive associations [12,
71]. One study used an immunoassay rather than circulating hormones to quantify prolactin levels and determined that postmenopausal women with high prolactin
immunoassay profiles had higher breast dense area and
lower non-dense area than those with lower prolactin
immunoassay readings [72].
We observed correlations between plasma RANK
pathway gene expression and hormone gene expression,
which is an indication of the crosstalk between these
markers and may provide further biological insights into
the complex pathways through which the markers influence MBD and breast cancer risk. Progesterone upregulates RANKL expression [24, 25] and interacts with the
RANK/RANKL pathway through signal transducer
and activator of transcription (STAT) signaling [26, 27],
while OPG mRNA transcription in healthy breast tissue is regulated by estrogen [73, 74]. Further clinical
studies are needed to characterize the interrelationships
between these markers and how they influence MBD and
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breast cancer development. The inverse correlations of
BMI with OPG gene expression we observed are similar to what has been reported for their circulating levels
[75] but we did not observe positive correlations of BMI
with ESR1 and PRL gene expression, in contrast to what
has been reported for their circulating levels [76]. Other
studies evaluating correlations of BMI with hormone
gene expression are needed.
Our study has several strengths. Study participants
were recruited among women attending annual routine
screening mammograms. We analyzed plasma hormone
gene expression rather than circulating hormone levels, and we did compare the gene expression to protein
levels in a subset of participants. However, we did not
compare the mRNA gene expression in the plasma to
the gene expression in the breast tissue since study participants were cancer-free women recruited during their
annual screening mammogram. Future studies integrating plasma gene expression, target tissue gene expression,
and circulating protein levels as biomarkers in elucidating MBD for breast cancer risk are encouraged.
One limitation of our study is that the sample size was
not large enough to perform mediation analyses between
hormone and RANK gene expression on MBD or to conduct analyses stratified by BMI and race. We did not profile plasma gene expression of other hormones such as
androgens and sex hormone-binding globulin, and parathyroid hormone, a known regulator of the RANK pathway. Future studies evaluating how these hormones are
associated with MBD will be needed.

Conclusions
In conclusion, we observed positive associations of ESR1,
RANK, and TNFRSF18 plasma gene expression with
VPD in postmenopausal women. Women with extremely
dense breasts had higher RANKL and OPG plasma
gene expression than women with entirely fatty breasts.
These findings require validation within other study
populations.
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